UCB’s anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP positive opinion for primary generalised tonic-clonic seizures
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a licence extension for its anti-epileptic drugs VIMPAT (lacosamide) and Lacosamide UCB (lacosamide) as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy1 (IGE)
IGEs (idiopathic generalised epilepsy) account for 20%–40% of all epilepsies2, characterized by different generalized seizure types (absence, myoclonic and PGTCS)3
Patients living with generalized tonic-clonic seizures have an increased risk of injury4 and those who experienced three or more in one year had a fifteen-fold increased risk of sudden unexpected death in epilepsy5
UCB awaits decision from the European Commission (EC) on the potential approval of this new VIMPAT® license extension in the European Union